deltatrials
Completed PHASE3 NCT00202436

Haemochromatosis:Phlebotomy Versus Erythrocytapheresis Therapy

Therapeutic Erythrocytapheresis as Treatment for Hemochromatosis Patients.

Sponsor: Atrium Medical Center

Conditions Hemochromatosis
Interventions Erythrocytapheresis Phlebotomy
Updated 6 times since 2017 Last updated: Oct 19, 2009 Started: Oct 31, 2004 Primary completion: Dec 31, 2008 Completion: Sep 30, 2009

Listed as NCT00202436, this PHASE3 trial focuses on Hemochromatosis and remains completed. Sponsored by Atrium Medical Center, it has been updated 6 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Mar 2022 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Mar 2022 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Atrium Medical Center
  • Maastricht University Medical Center
  • Radboud University Medical Center
  • Sanquin Research & Blood Bank Divisions
Data source: Sanquin Research & Blood Bank Divisions

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Maastricht, Netherlands